FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.
2 reports, 2 independent
Updated Aug 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted the New Drug Application (NDA) for encaleret from BridgeBio.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Barclays issues overweight rating on BridgeBio, linking it to FDA review of BBP-418 and market size comparison to Nvidia.1 source
FDA accepted NDA for BridgeBio's encaleret.1 source
Keep exploring
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.